Aegerion Pharmaceuticals, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$45.2M | −$26.7M | −$62.3M | −$60.6M | −$39.3M | −$13.6M |
| Net income | −$15.8M | −$15,776 | −$63.4M | −$62.3M | −$39.5M | −$14.3M |
| Total assets | $434.2M | $412.4M | $142.3M | $85.1M | $75.6M | $45.7M |
| Total liabilities | $318.7M | $252.1M | $29.3M | $24.7M | $18.4M | $4.7M |
| Equity | $115.5M | $160.3M | $113.0M | $60.4M | $57.2M | $41.1M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 28.5M | 29.4M | 28.8M | 21.3M | 21.2M | 17.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2015- Operating margin
- —
- Net margin
- —
- Return on equity
- −13.7%
- Return on assets
- −3.6%
- Return on capital (ROCE)
- −13.0%
- Liabilities / assets
- 73.4%
- Debt / equity
- 2.76×
- Book value / share
- $4.05
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2015- Altman Z″ (distress)
- -1.74distress
- Accruals / assets
- −7.3%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 11, 2016
- NT 10-Kmissed a reporting deadline ↗Feb 29, 2016
- NT 10-Qmissed a reporting deadline ↗Aug 11, 2015
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Broadfin Healthcare Master Fund Ltd10% owner | Nov 29, 2016 | D | 4.4M | — |
| Harshbarger BenjaminOfficer — General Counsel and Secretary | Nov 29, 2016 | D | 1,704 | — |
| Vanlent AnneDirector | Nov 29, 2016 | D | 4,000 | — |
| Thomas PaulDirector | Nov 29, 2016 | D | 36,978 | — |
| Smith Sandford DDirector | Nov 29, 2016 | D | 2,890 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsNov 29, 2016
- Shareholder voteNov 7, 2016
- Results of operationsNov 3, 2016
- Other material eventOct 24, 2016
- Other material eventOct 20, 2016
- Other material eventOct 3, 2016
- Results of operationsAug 9, 2016
- Other material eventAug 8, 2016
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SEC STAFF ACTIONAug 9, 2019
- T-3/AAug 8, 2019
- CORRESPAug 7, 2019
- UPLOADJul 30, 2019
- T-3Jul 18, 2019
- SC 13G/AFeb 14, 2017
- SC 13G/AFeb 14, 2017
- SC 13G/AFeb 8, 2017
- SC 13G/ASCHEDULE 13G/AJan 31, 2017
- SC 13G/ADec 12, 2016
- 15-12BDec 9, 2016
- EFFECTDec 8, 2016
- SC 13G/ASCHEDULE 13GDec 5, 2016
- 4Dec 1, 2016
- SC 13D/ADec 1, 2016
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.